Catalyst Pharmaceuticals (CPRX) Competitors

Geron (NASDAQ:GERN) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, community ranking, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Which has stronger valuation & earnings, GERN or CPRX?

Catalyst Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$240K	8,635.99	-$184.13M	-$0.33	-11.48
Catalyst Pharmaceuticals	$398.20M	4.61	$71.41M	$0.61	25.48

Does the media refer more to GERN or CPRX?

In the previous week, Geron had 2 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 4 mentions for Geron and 2 mentions for Catalyst Pharmaceuticals. Geron's average media sentiment score of 1.28 beat Catalyst Pharmaceuticals' score of 0.48 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Catalyst Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, GERN or CPRX?

Geron has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.

Does the MarketBeat Community prefer GERN or CPRX?

Catalyst Pharmaceuticals received 5 more outperform votes than Geron when rated by MarketBeat users. Likewise, 74.38% of users gave Catalyst Pharmaceuticals an outperform vote while only 69.53% of users gave Geron an outperform vote.

Company	Underperform	Outperform
Geron	Outperform Votes 477 69.53%	Underperform Votes 209 30.47%
Catalyst Pharmaceuticals	Outperform Votes 482 74.38%	Underperform Votes 166 25.62%

Do analysts prefer GERN or CPRX?

Geron currently has a consensus price target of $5.33, indicating a potential upside of 41.09%. Catalyst Pharmaceuticals has a consensus price target of $26.43, indicating a potential upside of 70.07%. Given Geron's higher probable upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Catalyst Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals have more ownership in GERN or CPRX?

73.7% of Geron shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 3.1% of Geron shares are held by insiders. Comparatively, 12.1% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is GERN or CPRX more profitable?

Catalyst Pharmaceuticals has a net margin of 17.93% compared to Catalyst Pharmaceuticals' net margin of -77,691.14%. Geron's return on equity of 26.56% beat Catalyst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-77,691.14%	-63.33%	-44.71%
Catalyst Pharmaceuticals	17.93%	26.56%	22.13%

Summary

Catalyst Pharmaceuticals beats Geron on 15 of the 17 factors compared between the two stocks.